Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 FinancialNewsMedia - Tue Jan 9, 9:25AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 1.2400 (+5.08%)
ONC.TO : 1.69 (+4.32%)
AMGN : 312.86 (+1.81%)
AMAM : 28.00 (+0.07%)
ELEV : 3.51 (-1.96%)
NKTX : 6.30 (-1.56%)
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis PR Newswire - Tue Oct 17, 2023

/PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq:...

NKTX : 6.30 (-1.56%)
Why Shares of Nkarta Are Slumping Tuesday Motley Fool - Tue Jun 27, 2023

The pharmaceutical stock dropped after announcing so-so clinical trial results.

CRSP : 53.55 (+0.49%)
NKTX : 6.30 (-1.56%)
Nkarta Announces Key Senior Leadership Team Appointments Globe Newswire - Mon Jul 25, 2022

Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...

NKTX : 6.30 (-1.56%)
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know Zacks - Tue Jun 7, 2022

The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

NKTX : 6.30 (-1.56%)
Nkarta to Participate at Upcoming Investor Conference Globe Newswire - Tue May 31, 2022

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 6.30 (-1.56%)
What Makes Nkarta, Inc. (NKTX) a New Buy Stock Zacks - Wed May 18, 2022

Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NKTX : 6.30 (-1.56%)
Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect? Zacks - Wed May 18, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive...

NKTX : 6.30 (-1.56%)
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development Globe Newswire - Mon May 16, 2022

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...

NKTX : 6.30 (-1.56%)
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights Globe Newswire - Thu May 12, 2022

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...

NKTX : 6.30 (-1.56%)

Barchart Exclusives

Stock Index Futures Climb as Fed Rate Cut Hopes Grow, Fed Speak and ECB Minutes in Focus Barchart - 1 hour ago
June S&P 500 E-Mini futures (ESM24) are up +0.40%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.44% this morning after three major U.S. benchmark indices ended the regular session in the green as higher-than-expected applications for U.S. unemployment benefits bolstered the case for rate cuts, with investors looking ahead to fresh comments from Federal Reserve officials. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot